Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951496 | 0.76 | TP53 (0.39) | TP53NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14983495 | 0.71 | TP53 (0.34) | TP53NPC1RAB9A | |
| SCHEMBL14983493 | 0.69 | MAPT (0.36) | TP53NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29564383 | 0.67 | TP53 (0.31) | TP53 | |
| SCHEMBL14983494 | 0.67 | MAPT (0.39) | TP53NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14983496 | 0.67 | TSHR (0.33) | TP53KMT2A | |
| SCHEMBL1477749 | 0.66 | TP53 (0.41) | TP53NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5951509 | 0.64 | ALDH1A1 (0.33) | TP53NPC1RAB9A | |
| SCHEMBL15780777 | 0.64 | — | — | |
| SCHEMBL2400555 | 0.64 | ORAI1 (0.40) | TP53RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| EP-0880517-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880517-A1 | QUINAZOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5814630-A | USEFUL AS RECEPTOR TYROSINE KINASE INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-09-29 | — | — | US | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030044-A1 | QUINAZOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| US-4870212-A | ALKYL BORATE AND ORGANOLITHIUM | ALDRICH-BORANES, INC. (US) | 1989-09-26 | — | — | US | disclosed |
| US-4870177-A | PYROLYSIS OF LITHIUM ORGANYLBORATES | ALDRICH-BORANES, INC. (US) | 1989-09-26 | — | — | US | disclosed |
| US-4855506-A | Process for lithium mono- and diorganylborohydrides | ALDRICH-BORANES, INC. (US) | 1989-08-08 | — | — | US | disclosed |
| US-4772751-A | EASILY SEPARATED FROM BY-PRODUCTS | ALDRICH-BORANES, INC. (US) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | TP53 106/4885NPC1 2338/4885RAB9A 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.